Brain Health Matters
Dr. Dale Bredesen
The FDA approved a new Alzheimer’s drug, Aduhelm, and it’s estimated to cost medicare $57 billion per year. In the wake of the approval, three FDA advisory panel members resigned and medical professionals, patients, and taxpayers are understably worried.
That’s a boatload of cash. Does it even work?
My guest on this week’s podcast believes that the approval occurred simply because neurodegenerative diseases are such a huge issue with so few effective treatments. Perhaps the review board felt they needed to green light something?
In case you didn’t know, neurodegenerative diseases are the third leading cause of death worldwide, but unless it’s a Hollywood actor or professional athlete that is ill, almost no one talks about brain health.
Listen & Learn:
- Why amyloid plaque is not all bad, and can even be neuroprotective
- Why mild cognitive impairment (MCI) is not mild at all
- How the “slow reaper” of neurodegenerative diseases makes them easy to overlook
- Insulin sensitivity, mild ketosis, fiber and fat for brain health
Links & Resources
ABOUT OUR GUEST
Dr. Bredesen is an expert in neurodegenerative diseases. He held faculty positions at UCSF, UCLA and the University of California, San Diego. He directed the Program on Aging at the Burnham Institute. He was the founding president/CEO of the Buck Institute. He’s the best-selling author of The End of Alzheimer's.
Nutritional Tip of the Week:
Like the Show?